Interestingly, FGFR3 was highly expressed in both the tumor samples from the PDX models and patients, implying a promising molecular target for LUSC, which had been suggested by other reports that either FGFR-targeted therapy alone or the combination of FGFR1-targeted therapy and chemotherapy could be beneficial in the treatment of LUSC [18, 22]. This evidence concerns the gene FGFR1 and neoplasm.